{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T03:01:12Z","timestamp":1725159672446},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1097\/jcn.0b013e3182675e2a","type":"journal-article","created":{"date-parts":[[2013,7,4]],"date-time":"2013-07-04T01:48:48Z","timestamp":1372902528000},"page":"E47-E54","source":"Crossref","is-referenced-by-count":2,"title":["Aldosterone Antagonists in Heart Failure"],"prefix":"10.1097","volume":"28","author":[{"given":"Susan E.","family":"Miller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren\u00e9 J.","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"15","key":"R1-19-20210128","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2008.11.013","article-title":"American College of Cardiology Foundation; American Heart Association. 2009 Focused update incorporated into the ACCAHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology FoundationAmerican Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation.","volume":"53","author":"Hunt","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"R4-19-20210128","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2165\/00129784-200707040-00002","article-title":"Pharmacologic therapy of chronic heart failure.","volume":"7","author":"Hamad","year":"2007","journal-title":"Am J Cardiovasc Drugs"},{"issue":"10","key":"R5-19-20210128","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure.","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"issue":"14","key":"R6-19-20210128","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"issue":"3","key":"R8-19-20210128","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/MED.0b013e3283390fa4","article-title":"Aldosterone and cardiovascular disease.","volume":"17","author":"Carey","year":"2010","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"5","key":"R9-19-20210128","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.pcad.2009.12.003","article-title":"Aldosterone and mineralocorticoid receptors in the cardiovascular system.","volume":"52","author":"Funder","year":"2010","journal-title":"Prog Cardiovasc Dis"},{"issue":"6","key":"R10-19-20210128","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMra035279","article-title":"Managing hyperkalemia caused by inhibition of the renin-angiotensin-aldosterone system.","volume":"351","author":"Palmer","year":"2004","journal-title":"N Engl J Med"},{"issue":"5","key":"R11-19-20210128","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrneph.2010.30","article-title":"Aldosterone: effects on the kidney and cardiovascular system.","volume":"6","author":"Briet","year":"2010","journal-title":"Nat Rev Nephrol"},{"issue":"23","key":"R12-19-20210128","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMra000050","article-title":"Aldosterone in congestive heart failure.","volume":"345","author":"Weber","year":"2001","journal-title":"N Engl J Med"},{"issue":"6","key":"R13-19-20210128","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.2215\/CJN.01410210","article-title":"Aldosterone: role in edematous disorders, hypertension, chronic renal failure and metabolic syndrome.","volume":"5","author":"Schrier","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"R15-19-20210128","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1172\/JCI117269","article-title":"Mineralocorticoids, hypertension and cardiac fibrosis.","volume":"93","author":"Young","year":"1994","journal-title":"J Clin Invest"},{"issue":"1","key":"R16-19-20210128","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0008-6363(97)00097-7","article-title":"Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion.","volume":"35","author":"Sun","year":"1997","journal-title":"Cardiovasc Res"},{"issue":"5","key":"R18-19-20210128","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ejheart.2004.04.013","article-title":"The clinical implications of aldosterone escape in congestive heart failure.","volume":"6","author":"Struthers","year":"2004","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"R19-19-20210128","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10741-005-2352-2","article-title":"The role of aldosterone blockade in patients with heart failure.","volume":"10","author":"Pitt","year":"2005","journal-title":"Heart Fail Rev"},{"issue":"4","key":"R20-19-20210128","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/eurheartj\/ehp026","article-title":"Aldosterone blockage in patients with heart failure and a reduced left ventricular ejection fraction.","volume":"30","author":"Pitt","year":"2009","journal-title":"Eur Heart J"},{"issue":"9507","key":"R22-19-20210128","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S0140-6736(06)68074-4","article-title":"Controversies in ventricular remodeling.","volume":"367","author":"Opie","year":"2008","journal-title":"Lancet"},{"issue":"3","key":"R23-19-20210128","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/HCO.0b013e32832a11ff","article-title":"Strategies to attenuate pathological remodeling in heart failure.","volume":"24","author":"Eapen","year":"2009","journal-title":"Curr Opin Cardiol"},{"issue":"11","key":"R24-19-20210128","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/j.jacc.2003.12.053","article-title":"Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure.","volume":"43","author":"Wong","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"R26-19-20210128","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/eurheartj\/ehn543","article-title":"Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials.","volume":"30","author":"Ezekowitz","year":"2009","journal-title":"Eur Heart J"},{"issue":"6","key":"R27-19-20210128","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1007\/s11936-008-0044-7","article-title":"Treatment of patients with heart failure and preserved ejection fraction.","volume":"10","author":"Deswal","year":"2008","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"R28-19-20210128","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10741-005-2345-1","article-title":"Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis.","volume":"10","author":"Sicca","year":"2005","journal-title":"Heart Fail Rev"},{"issue":"4","key":"R30-19-20210128","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1046\/j.1523-1755.2000.00983.x","article-title":"Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology.","volume":"57","author":"Delyani","year":"2000","journal-title":"Kidney Int"},{"issue":"4","key":"R31-19-20210128","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0002-9343(00)00496-4","article-title":"Drug-induced hyperkalemia: old culprits and new offenders.","volume":"109","author":"Parazella","year":"2000","journal-title":"Am J Med"},{"issue":"6","key":"R32-19-20210128","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1056\/NEJMp048144","article-title":"Treatment of heart failure with spironolactonetrials and tribulations.","volume":"351","author":"McMurray","year":"2004","journal-title":"N Engl J Med"},{"issue":"2","key":"R33-19-20210128","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0735-1097(02)02694-3","article-title":"Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines.","volume":"41","author":"Bozkurt","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R34-19-20210128","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.108.778811","article-title":"Mukherjee R on behalf of the EPHESUS Investigators. Serum potassium and clinical outcomes in the eplerenone post acute myocardial infarction heart failure efficacy and survival study (EPHESUS).","volume":"118","author":"Pitt","year":"2008","journal-title":"Circulation"},{"issue":"6","key":"R35-19-20210128","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.cardfail.2010.04.005","article-title":"Heart Failure Society of America 2010 guideline executive summary: executive summary: HFSA 2010 comprehensive heart failure practice guideline.","volume":"16","author":"Lindenfeld","year":"2010","journal-title":"J Card Fail"},{"issue":"3","key":"R36-19-20210128","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.amjmed.2008.10.028","article-title":"The management of hyperkalemia in patients with cardiovascular disease.","volume":"122","author":"Khanna","year":"2009","journal-title":"Am J Med"},{"issue":"6","key":"R37-19-20210128","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.hrthm.2009.02.005","article-title":"Aldosterone blockade attenuates development of an electrophysiological substrate associated with ventricular tachyarrhythmias in heart failure.","volume":"6","author":"Stambler","year":"2009","journal-title":"Heart Rhythm"},{"issue":"1013","key":"R38-19-20210128","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/pgmj.2008.072058","article-title":"Understanding the risk of hyperkalemia in heart failure: role of aldosterone antagonism.","volume":"86","author":"Poggio","year":"2010","journal-title":"Postgrad Med J"}],"container-title":["Journal of Cardiovascular Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCN.0b013e3182675e2a","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:45:21Z","timestamp":1620956721000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005082-201311000-00019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/jcn.0b013e3182675e2a","relation":{},"ISSN":["0889-4655"],"issn-type":[{"value":"0889-4655","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}